Skip to main content
. 2023 Feb 28;9(2):17. doi: 10.3390/ncrna9020017

Figure 8.

Figure 8

In vivo miR-30d-5p inhibition decreases both CD4+ pre-effector-like and CM T cells in the spleen. (A) Representative FACS plots indicating the percentage of CD4+ naïve, EM, CM, and pre-effector-like T cells in the spleen of the control inhibitor (left, blue) and miRNA inhibitor (right, red) treatment groups. (B,C) Percentage (left) and total cell numbers (right) of (B) CD4+ pre-effector-like T cells and (C) CD4+ CM T cells in the spleen of sham mice (n = 6, left, grey), mice treated with a control inhibitor (n = 6, middle, blue), or mice treated with the miR-30d-5p inhibitor (n = 6, right, red). Data are presented as mean ± SD. * p ≤ 0.05, Kruskal–Wallis with Dunn’s post hoc test.